SequelSEC

NEKTAR THERAPEUTICS NKTR

Pharmaceutical Preparations · CIK 0000906709 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$54.59M
Fiscal year ended 2026-06-30
Operating income
-$140.73M
Fiscal year ended 2026-06-30
Free cash flow
-$234.03M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$318.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$11.08Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue5.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin100.0%97th
CapEx / revenue0.3%21th
Revenue YoY growth-43.9%26th
FCF margin-377.8%37th
Current ratio4.97x60th
Net margin-297.1%44th
R&D / revenue212.4%54th
Operating margin-253.7%49th

NEKTAR THERAPEUTICS (NKTR) reported revenue of $54.59M and net income of -$157.13M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from NEKTAR THERAPEUTICS’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NEKTAR THERAPEUTICS income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$54.59M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$140.73M
Net income-$157.13M
Research & development$131.77M
Weighted-average diluted sharesUnavailable
Pretax income-$153.11M
Income tax expense$64.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$53.46M
Selling & marketingUnavailable

Balance

NEKTAR THERAPEUTICS balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$39.27M
Total assets$1.10B
Current assets$739.40M
Total liabilities$192.01M
Current liabilities$70.98M
Total equity incl. NCI$903.12M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$24.89M

Cash flow

NEKTAR THERAPEUTICS cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$233.79M
Capital expenditures$244.00K
Investing cash flow-$844.40M
Financing cash flow$1.07B
Net change in cash-$3.72M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$693.00K

Derived

NEKTAR THERAPEUTICS derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$234.03M
Gross marginUnavailable
Operating margin-257.8%
FCF margin-428.7%
SBC / revenueUnavailable
Current ratio10.42x
Revenue YoY growth-27.2%
Net margin-287.8%
R&D / revenue241.4%
CapEx / revenue0.4%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NKTR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-13View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.